Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare small-vessel vasculitis of unknown etiology first described by McDuffie We hypothesize that omalizumab is safe and effective in milder forms of HUVS, but not in those involving the kidney and/or the lung, which usually require immunosuppressive drugs
Nucera, E., Basta, F., Buonomo, A., Mezzacappa, S., Margiotta, D., Antonelli Incalzi, R., Schiavino, D., A Case of Hypocomplementemic Urticarial Vasculitis Syndrome Successfully Treated With Omalizumab, <<JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY>>, 2017; (27): 382-384 [http://hdl.handle.net/10807/120188]
A Case of Hypocomplementemic Urticarial Vasculitis Syndrome Successfully Treated With Omalizumab
NuceraPrimo
;F; Buonomo;A; Mezzacappa;Dp; Antonelli Incalzi;R; SchiavinoUltimo
2017
Abstract
Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare small-vessel vasculitis of unknown etiology first described by McDuffie We hypothesize that omalizumab is safe and effective in milder forms of HUVS, but not in those involving the kidney and/or the lung, which usually require immunosuppressive drugs
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
